Research News

Therapeutic manipulation of HDL fails to benefit adults with heart disease

BMJ 2012; 345 doi: (Published 13 November 2012) Cite this as: BMJ 2012;345:e7643

Dalcetrapib increases serum concentrations of high density lipoprotein (HDL) cholesterol, and Hoffmann-La Roche developed this new drug in response to observational evidence that higher concentrations were associated with a lower risk of cardiovascular disease. Dalcetrapib failed to prevent cardiovascular …

Sign in

Log in through your institution

Free trial

Register for a free trial to to receive unlimited access to all content on for 14 days.
Sign up for a free trial